
CLAIMS

[Claim 1]

A pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one having the following structure, or a pharmaceutically acceptable salt thereof, and sodium lauryl sulfate:

[Formula 1]



[Claim 2]

The composition according to claim 1, comprising sodium lauryl sulfate in a range of 0.05 to 15 parts by mass, relative to 1 part by mass of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one.

[Claim 3]

The composition according to claim 1 or 2, comprising sodium lauryl sulfate in a range of 0.2 to 5 parts by mass, relative to 1 part by mass of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one.

[Claim 4]

The composition according to any one of claims 1 to 3, further comprising a disintegrant.

[Claim 5]

The composition according to claim 4, wherein the disintegrant is selected from the group consisting of crospovidone, carmellose sodium, and carmellose calcium.

[Claim 6]

The composition according to claim 5, wherein the disintegrant is crospovidone.

[Claim 7]

The composition according to claim 5 or 6, comprising crospovidone in a range of 0.1 to 20 parts by mass, relative to 1 part by mass of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one.

[Claim 8]

The composition according to claim 5, comprising carmellose sodium in a range of 0.1 to 5 parts by mass, relative to 1 part by mass of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one.

[Claim 9]

The composition according to claim 5, comprising carmellose calcium in a range of 0.1 to 5 parts by mass, relative to 1 part by mass of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one.

[Claim 10]

The composition according to any one of claims 1 to 9, wherein the composition comprises an excipient selected from the group consisting of D-mannitol and lactose.

[Claim 11]

The composition according to any one of claims 1 to 10, wherein the composition comprises crystalline cellulose.

[Claim 12]

A method for improving the dissolution of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one from a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-

dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one or a pharmaceutically acceptable salt thereof, wherein the method comprises adding sodium lauryl sulfate to the pharmaceutical composition.

[Claim 13]

A method for improving the absorption of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one, wherein the method comprises adding sodium lauryl sulfate to a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one or a pharmaceutically acceptable salt thereof.

[Claim 14]

A method for improving the manufacturability of a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one or a pharmaceutically acceptable salt thereof, wherein the method comprises adding sodium lauryl sulfate to the pharmaceutical composition.

[Claim 15]

Use of sodium lauryl sulfate for improving the dissolution of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one or a pharmaceutically acceptable salt thereof.

[Claim 16]

Use of sodium lauryl sulfate for improving the absorption of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one or a pharmaceutically acceptable salt thereof.

[Claim 17]

Use of sodium lauryl sulfate for improving the manufacturability of a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one or a pharmaceutically acceptable salt thereof.

[Claim 18]

Use of sodium lauryl sulfate for producing a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one or a pharmaceutically acceptable salt thereof.

[Claim 19]

Use of a pharmaceutical composition according to any of claims 1 to 11 for the manufacture of a medicament for treating or preventing a tumor.